(Q53063068)

11 May 2018

editorial

0 references

title

Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. (English)

1 reference

11 May 2018

1 reference

1 reference

1

1 reference

11 May 2018

publication date

11 March 2014

1 reference

11 May 2018

Expert Review of Hematology

published in

1 reference

11 May 2018

volume

7

1 reference

11 May 2018

issue

3

1 reference

11 May 2018

page(s)

317-319

1 reference

11 May 2018

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

BiTEs: bispecific antibody constructs with unique anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Bispecific antibodies engage T cells for antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.896190

10.1586/17474086.2014.896190

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018